Relation Between Substance Use and Pain, in Patients Suffering or Surviving From Cancer and Followed in France

Pain Clinical Trial

— CAPS  

Official title:

Study of the Relation Between the Consumption of Psychoactive Substances and Pain, in Patients Suffering or Surviving From Cancer and Followed in France: Cross-sectional Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05684939
• Other study ID #: RNI 2022 BALAYSSAC
• Status: Completed
• Start date: January 27, 2023
• Est. completion date: March 20, 2023

Study information

• Verified date: December 2022
• Source: University Hospital, Clermont-Ferrand
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Pain is one of the most prevalent symptoms during and after cancer. Pain can be the consequence of several situations (disease progression, surgery, and anticancer drugs). However, pain can frequently be associated with a substance use disorder (alcohol, tobacco, drugs, and illicit products such as cannabis). The relationship between substance use and pain is known to be complex and interdependent, i.e. pain can reinforce substance use and substance use can promote pain. However, few data in the literature are available on the use of psychoactive substances in relation to pain in the context of cancer (cancer patients and cancer survivors). Moreover, the scientific literature agrees on the fact that these elements are little studied and underestimated in the clinic.

The investigators hypothesize that, in cancer patients or cancer survivors, the prevalence of the use of psychoactive substances would be higher in the presence of pain, and would be associated with its intensity and its impact on the quality Health-Related Living (HRQoL).

The main objective of this study will be to compare, in an adult population of patients suffering from cancer or having had cancer, the prevalence of the consumption of psychoactive substances in painful patients compared to non-painful patients.

Description:

Patients will answer to an online questionnaire thanks to associations of cancer patients and social networks, in order to explore their substance use and pain status.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2010
• Est. completion date: March 20, 2023
• Est. primary completion date: March 20, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patient, male or female, declaring himself as suffering or having suffered from cancer and recruited as such via appropriate communication systems (patient associations, etc.)

Exclusion Criteria:

• Difficulty to understand French language

• Residence outside France (will be verified by the information from the department at the start of the questionnaire)

• Patient close relative

• Protected adults

Related Conditions & MeSH terms

• Cancer
• Pain
• Substance Use
• Substance-Related Disorders

Intervention

Behavioral:
• Questionnaire (patient reported outcome)
Online self-administered questionnaire exploring substance use, pain, chemotherapy-induced peripheral neuropathy, health-related quality of life, anxiety, depression, social and material deprivation, patients and oncological charactericitcs, and intercurrent pathologies

Locations

Country	Name	City	State
France	CHU Clermont-Ferrand	Clermont-Ferrand

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	substance use	Legal: alcohol, tobacco, electronic cigarette, psychotropic drugs (benzodiazepines, z-drugs, and opioids), CBD, and other susbtances Illegal: cannabis, and other drugs; At least once in the past year, at least once in the past month, at least once in the past week, or at least once a day	day 1
Secondary	Pain severity	Brief pain inventory	day 1
Secondary	Neuropathic pain	DN4 interview questionnaire	day 1
Secondary	Analgesic use	Ongoing analgesic drugs	day 1
Secondary	Chemotherapy-induced peripheral neuropathy	QLQ-CIPN20 questionnaire	day 1
Secondary	Health-related quality of life and symptoms	QLQ-C30 questionnaire	day 1
Secondary	Anxiety and depression	HADS questionnaire	day 1
Secondary	Material and social deprivation	EPICES questionnaire	day 1
Secondary	Sociodemographic characteristics of patient	age, sex, height, weight, body mass index, area of residence (urban or rural), socio-professional status (INSEE), and department	day 1
Secondary	Oncological characteristic	type of cancer, date of cancer diagnosis, and type of treatment (received and/or ongoing)	day 1
Secondary	Intercurrent pathologies	open question	day 1